



We are looking for a talented and motivated scientist (PhD student) to advance an exciting research project:



Early Stage Researcher (ESR14)

Chemotherapy-induced functional myocardial alterations: is a HFpEF stage preceding HFrfEF?

About INSPIRE – A European Training Network in Safety Pharmacology


The vision of INSPIRE is to advance and “inspire” Safety Pharmacology by exploring new technological capabilities to addressing emerging cardiovascular safety concerns. Hereto, INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). Key innovative aspects of INSPIRE include: i) *in vitro* humanized cardiomyocytes assays, ii) unparalleled *in vivo* hardware/software solutions, iii) *in silico* predictions of haemodynamics, iv) mass spectroscopy imaging of drug exposure, v) exploration of mechanisms of late-onset CV toxicity, as observed in cardio-oncology, and vi) early integration of feedback from industry and regulators.

Overall, INSPIRE constitutes a multidisciplinary and intersectoral training programme with a balanced combination of hands-on research training, intersectoral secondments, local courses and network-wide events on scientific and transferable skills, enabling future R&I collaborations. Hence, INSPIRE will equip the future generation of SP scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic industry.

Description of the PhD project

Scientific Objectives:

- Evaluating chemotherapy-induced functional and molecular alterations related to passive stiffness and diastolic dysfunction.
- Exploration of diastolic dysfunction (or even heart failure with preserved ejection fraction, HFpEF) as a potential clinical precursor of heart failure with reduced ejection fraction (HFrfEF) in cardiovascular toxicity.



Tasks and Responsibilities:

- You perform independently scientific research within a collaborative international research consortium (training network).
- You deliver written reports of your research on a regular basis.
- You prepare a doctoral thesis on Chemotherapy-induced functional myocardial alterations.
- You publish scientific articles related to the research project of the assignment.
- You (may) contribute (limited) to teaching activities.
- You (may) support the valorization of research results into tangible deliverables
- You participate to scientific meetings and conferences to present your research to the scientific community.
- You actively participate in outreach activities aimed to promote your scientific research to a wider audience.
- The selected candidate will get in contact with the other members of this international consortium and will benefit from the tailored training programme.



- The selected candidate will take part in the following planned secondments: 1. Academic secondment to Maastricht University (2 months, the Netherlands) for MSI acquisition and analysis. 2. Non-academic secondment to IMEC (7 months, Belgium) for evaluating drug effects on patient-derived iPSC by using IMEC's lab-on-chip platform. ESR14 has access to clinical research infrastructure through UZA.

About the University of Antwerp – Cardiovascular Diseases Research Group

The research group of Cardiovascular Diseases is headed by prof. dr. Hein Heidbuchel. Based on fundamental, clinical and translational research, the group aims to understand the pathophysiological mechanisms causing cardiovascular diseases, in order to propose new treatments. Together with Medical Genetics (MEDGEN) and Physiopharmacology (FYSFAR), this group is member of the Genetics, Pharmacology and Physiopathology of Heart, Blood Vessels and Skeleton (GENCOR) department. More information about the team is available at: <https://www.uantwerpen.be/en/research-groups/cardiovascular-diseases/>.

The University of Antwerp is a young, dynamic and forward-thinking university. It is a merger (2003) of the former three university institutions in Antwerp (RUCA, UFSIA and UIA). It ranks 18th in the "QS Top 50 Under 50 2020". The University has ca. 1850 PhD students, 680 tenured professors, over 350 assistants and over 3400 tenured researcher and education staff members. It produces over 3600 peer-reviewed scientific publications per year. The European Commission has awarded the University the "HR Excellence in Research" quality label.

Profile & requirements

- ✓ Applicants must hold a MSc or equivalent in the field of Medicine, Pharmaceutical or Biomedical Sciences.
- ✓ Applicants must have a solid knowledge of cardiovascular (patho)physiology and methods for investigating this.
- ✓ Applicants can be of any nationality, but have to comply with the "Mobility Rule (cf. infra)".
- ✓ Applicants must have an ability to understand and express themselves in both written and spoken English to a level that is sufficiently high for them to derive the full benefit from the network training.
- ✓ Applicants must be eligible to enrol on a PhD programme at the host institution (or at a designated university, in case the host institution is a non-academic organisation).
- ✓ Applicants must have the necessary academic skills and background to make the success of a doctoral degree.
- ✓ **H2020 MSCA Mobility Rule:** researchers must not have resided or carried out their main activity (work, studies, etc.) in the country of the host organisation for more than 12 months in the 3 years immediately before the recruitment date. Compulsory national service, short stays such as holidays, and time spent as part of a procedure for obtaining refugee status are not taken into account.
- ✓ **H2020 MSCA eligibility criteria:** Early Stage Researchers (ESRs) must be, at the date of recruitment by the host organisation, in the first four years (full-time equivalent research experience) of their research careers and have not been awarded a doctoral degree. Full-Time Equivalent Research Experience is measured from the date when the researcher obtained the degree entitling him/her to embark on a doctorate (either in the country in which the degree was obtained or in the country in which the researcher is recruited, even if a doctorate was never started).

Benefits

- ✓ The selected candidate will be employed by the host organisation for 36 months.
- ✓ A competitive salary plus allowances. Moreover, funding is available for technical and personal skills training and participation in international research events.
- ✓ The selected candidate will benefit from the designed training programme offered by the host organisation and the INSPIRE consortium.
- ✓ The selected candidate will participate in international secondments to other organisations within the INSPIRE network and in outreach activities targeted at a wide audience.

Please, find additional information in the [Information note for Marie Skłodowska-Curie ITN fellows](#)

Application

Interested candidates are invited to apply for this position by filing in the application form on our website (www.inspire-safety-pharmacology.eu), via this link: <https://www.uantwerpen.be/en/projects/inspire-safety-pharmacology/job-openings/submit-your-applicat/>.

For additional information

Dr. Constantijn Franssen
Email: constantijn.franssen@uza.be
Phone: +32 3 821 48 39

